Updated UK Recommendations for HER2 assessment in breast cancer

Emad A Rakha, Sarah E Pinder, John M S Bartlett, Merdol Ibrahim, Jane Starczynski, Pauline J Carder, Elena Provenzano, Andrew Hanby, Sally Hales, Andrew H S Lee, Ian O Ellis, National Coordinating Committee for Breast Pathology, R Adamson, Al-Sam, M Ashton, N Anderson, G Callagy, S Cawthorne, D Coleman, N S Dallimore, R Deb, D Fish, A Girling, S Hales, K M Horgan, M Howe, S Kodikara, K Lea, L Jones, G McCusker, E Mallon, D M Parham, N Patel, J Patnick, C M Quinn, D Rowlands, S J Sellars, T J Stephenson, C A Wells, R Wilson, Emad A Rakha, Sarah E Pinder, John M S Bartlett, Merdol Ibrahim, Jane Starczynski, Pauline J Carder, Elena Provenzano, Andrew Hanby, Sally Hales, Andrew H S Lee, Ian O Ellis, National Coordinating Committee for Breast Pathology, R Adamson, Al-Sam, M Ashton, N Anderson, G Callagy, S Cawthorne, D Coleman, N S Dallimore, R Deb, D Fish, A Girling, S Hales, K M Horgan, M Howe, S Kodikara, K Lea, L Jones, G McCusker, E Mallon, D M Parham, N Patel, J Patnick, C M Quinn, D Rowlands, S J Sellars, T J Stephenson, C A Wells, R Wilson

Abstract

Human epidermal growth factor receptor 2 (HER2) overexpression is present in approximately 15% of early invasive breast cancers, and is an important predictive and prognostic marker. The substantial benefits achieved with anti-HER2 targeted therapies in patients with HER2-positive breast cancer have emphasised the need for accurate assessment of HER2 status. Current data indicate that HER2 test accuracy improved following previous publication of guidelines and the implementation of an external quality assessment scheme with a decline in false-positive and false-negative rates. This paper provides an update of the guidelines for HER2 testing in the UK. The aim is to further improve the analytical validity and clinical utility of HER2 testing by providing guidelines of test performance parameters, and recommendations on the postanalytical interpretation of test results. HER2 status should be determined in all newly diagnosed and recurrent breast cancers. Testing involves immunohistochemistry with >10% complete strong membrane staining defining a positive status. In situ hybridisation, either fluorescent or bright field chromogenic, is used either upfront or in immunohistochemistry borderline cases to detect the presence of HER2 gene amplification. Situations where repeat HER2 testing is advised are outlined and the impact of genetic heterogeneity is discussed. Strict quality control and external quality assurance of validated assays are essential. Testing laboratories should perform ongoing competency assessment and proficiency tests and ensure the reliability and accuracy of the assay. Pathologists, oncologists and surgeons involved in test interpretation and clinical use should adhere to published guidelines and maintain accurate performance and consistent interpretation of test results.

Keywords: BREAST; BREAST CANCER; BREAST PATHOLOGY.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Figures

Figure 1
Figure 1
Recommended HER2 scoring algorithm for immunohistochemistry (IHC) and in situ hybridisation (ISH).
Figure 2
Figure 2
Pathway for HER2 testing.

References

    1. Slamon DJ, Godolphin W, Jones LA, et al. . Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707–12.
    1. Ross JS, Fletcher JA. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol 1999;112(1 Suppl 1):S53–67.
    1. Gianni L, Dafni U, Gelber RD, et al. . Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 2011;12:236–44.
    1. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. . Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659–72.
    1. Gianni L, Eiermann W, Semiglazov V, et al. . Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010;375:377–84.
    1. Geyer CE, Forster J, Lindquist D, et al. . Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733–43.
    1. Baselga J, Bradbury I, Eidtmann H, et al. . Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012;379:633–40.
    1. Di Leo A, Gomez HL, Aziz Z, et al. . Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008;26:5544–52.
    1. Seidman AD, Berry D, Cirrincione C, et al. . Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008;26:1642–9.
    1. Untch M, Rezai M, Loibl S, et al. . Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 2010;28:2024–31.
    1. Wolff AC, Hammond ME, Schwartz JN, et al. . American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118–45.
    1. Perez EA, Suman VJ, Davidson NE, et al. . HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 2006;24:3032–8.
    1. Taucher S, Rudas M, Mader RM, et al. . Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer. Wien Klin Wochenschr 2004;116:26–31.
    1. Ellis IO, Bartlett J, Dowsett M, et al. . Best Practice No 176: updated recommendations for HER2 testing in the UK. J Clin Pathol 2004;57:233–7.
    1. Pathology reporting of breast disease. A Joint Document Incorporating the Third Edition of the NHS Breast Screening Programme's Guidelines for Pathology Reporting in Breast Cancer Screening and the Second Edition of The Royal College of Pathologists’ Minimum Dataset for Breast Cancer Histopathology. January2005. NHSBSP Pub. No 58 p.
    1. Walker RA, Bartlett JM, Dowsett M, et al. . HER2 testing in the UK: further update to recommendations. J Clin Pathol 2008;61:818–24.
    1. Hammond ME, Hayes DF, Dowsett M, et al. . American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28:2784–95.
    1. Carlson RW, Moench SJ, Hammond ME, et al. . HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw 2006;4(Suppl 3):S1–22; quiz S3–4.
    1. Middleton LP, Price KM, Puig P, et al. . Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases. Arch Pathol Lab Med 2009;133:775–80.
    1. Chen X, Yuan Y, Gu Z, et al. . Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis. Breast Cancer Res Treat 2012;134: 957–67.
    1. Wolff AC, Hammond ME, Hicks DG, et al. . Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013;31:3997–4013.
    1. Arnedos M, Nerurkar A, Osin P, et al. . Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann Oncol 2009;20: 1948–52.
    1. Lee AH, Key HP, Bell JA, et al. . Concordance of HER2 status assessed on needle core biopsy and surgical specimens of invasive carcinoma of the breast. Histopathology 2012;60:880–4.
    1. Greer LT, Rosman M, Mylander WC, et al. . Does breast tumor heterogeneity necessitate further immunohistochemical staining on surgical specimens? J Am Coll Surg 2013;216:239–51.
    1. Durgapal P, Mathur SR, Kalamuddin M, et al. . Assessment of her-2/neu status using immunocytochemistry and fluorescence in situ hybridization on fine-needle aspiration cytology smears: Experience from a tertiary care centre in india. Diagn Cytopathol 2014;42:726–31.
    1. Zustin J, Boddin K, Tsourlakis MC, et al. . HER-2/neu analysis in breast cancer bone metastases. J Clin Pathol 2009;62:542–6.
    1. Penault-Llorca F, Coudry RA, Hanna WM, et al. . Experts’ opinion: Recommendations for retesting breast cancer metastases for HER2 and hormone receptor status. Breast 2013;22:200–2.
    1. Lee AH, Key HP, Bell JA, et al. . The effect of delay in fixation on HER2 expression in invasive carcinoma of the breast assessed with immunohistochemistry and in situ hybridisation. J Clin Pathol 2014;67:573–5.
    1. Lundgaard Hansen B, Winther H, Moller K. Excessive section drying of breast cancer tissue prior to deparaffinisation and antigen retrieval causes a loss in HER2 immunoreactivity. Immunocytochemistry 2008;6:Run 76 117–22.
    1. Press MF, Sauter G, Bernstein L, et al. . Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 2005;11:6598–607.
    1. Pauletti G, Dandekar S, Rong H, et al. . Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000;18:3651–64.
    1. Sauter G, Lee J, Bartlett JM, et al. . Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009;27:1323–33.
    1. Arnould L, Roger P, Macgrogan G, et al. . Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH, CISH and SISH vs FISH). Mod Pathol 2012;25:675–82.
    1. Risio M, Casorzo L, Redana S, et al. . HER2 gene-amplified breast cancers with monosomy of chromosome 17 are poorly responsive to trastuzumab-based treatment. Oncol Rep 2005;13:305–9.
    1. Perez EA, Reinholz MM, Hillman DW, et al. . HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol 2010;28:4307–15.
    1. Hanna WM, Ruschoff J, Bilous M, et al. . HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Mod Pathol 2014;27:4–18.
    1. Bartlett AI, Starcyznski J, Robson T, et al. . Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition. Am J Clin Pathol 2011;136:266–74.
    1. Ohlschlegel C, Zahel K, Kradolfer D, et al. . HER2 genetic heterogeneity in breast carcinoma. J Clin Pathol 2011;64:1112–16.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다